When Robert Noyce and Gordon Moore founded Intel in 1968, they came up with what they called the “Goldilocks strategy.” They wanted to make memory chips, and started with three very different technologies. One was too easy for rivals to copy. Another added too much complexity. “And the third one, using a different kind of transistor, called a MOS transistor, turned out to be just right,” Moore said in an interview years later.
Big pharma Merck reported stellar results for its phase-two hepatitis C (HCV) drug trials Thursday, sparking debate among analysts over its potential to take market share from leader Gilead Sciences. At the International Liver Congress in London, Merck (MRK) reported a 98% cure rate in patients with hepatitis C genotype 1 who took a combination of its drug candidates MK-5172 and MK-8742. With the two potentially combined in one pill
Big pharma Merck (MRK) reported stellar results for its phase-two hepatitis C drug trials as the heavy hitters in the field rolled out their latest data Thursday at the International Liver Congress. Merck reported a 98% cure rate in patients with hepatitis C genotype 1 who took a combination of its drug candidates MK-5172 and MK-8742. With the two combined in one pill taken once per day, the pairing rivals the convenience and effectiveness of